relevant clinical parameters, including disease status, stage and histology, and we verified key results from selected studies (for example, survival plots; see Online Methods). To avoid ambiguities in outcome annotation, we restricted the results presented herein to the ~18,000 cases with overall survival data. We further confirmed the consistency and quality of integrated data sets and curated annotations by assessing the concordance between molecularly inferred versus clinically reported patient gender. In all, 98% of tumors were gender-concordant, with less than 2% of tumors affected by probable annotation errors (such as 'off-by-one' mismatches) ( Supplementary Fig. 1a-c) . All microarray studies in PRECOG were consistently normalized and pre-processed (see Online Methods) and associations between gene expression and survival were assessed by univariate Cox regression.
To compare prognostic associations across independent data sets, and to minimize the confounding influence of batch effects, the statistical associations between genes and clinical outcomes were assessed by z-scores. Z-scores are directly related to P values, but they conveniently encode both the directionality and robustness of statistical associations (Supplementary Fig. 1d ). Moreover, z-scores have a straightforward interpretation; they represent the number of s.d. from the mean of a normal distribution. For example, |z| > 1.96 is equivalent to a two-sided P < 0.05 (Supplementary Fig. 1d ). Unlike parameters such as hazard ratios, z-scores are independent of different timescales measuring survival follow-up times, and of the range/scale of predictor variables, permitting direct comparison across studies and platforms. To facilitate cross-cancer analyses, z-scores for individual studies were combined to yield 'meta-z-scores' for the prognostic significance of each gene in each cancer type (Supplementary Data 1). We observed high concordance between meta-z-scores and z-scores, where the latter were obtained by first merging expression data from multiple studies of the same cancer (for example, lung adenocarcinoma, Spearman's R = 0.9, P < 2.2 × 10 −16 ; see Online Methods). To further evaluate the robustness of the meta-z metric, we calculated a global meta-z-score for each gene across all cancers, more than one of the 39 distinct cancer histologies for which meta-z-scores were computed, while the remaining one-third are prognostic in only a single histology; the latter are cancer-specific. Right, same analysis shown at left but applied to randomly shuffled gene labels for each cancer in PRECOG. On the basis of 100,000 trials, the empirical P value for the observed enrichment of shared genes is P < 10 −5 (Monte Carlo simulation).
(d) Left, heat map showing genes (rows) clustered by association between expression levels and survival outcomes across 166 individual cancer studies (columns). Z-scores represent the statistical significance of each gene's association with survival, with poor prognosis genes in red, and favorable prognosis genes in green. All identified clusters were ranked by compound scores that integrate cluster size with the prognostic significance of genes within each cluster; the five top-ranking clusters are shown (left). Right, representative functional enrichments for each of the five clusters, determined by analyzing annotated gene sets with a Bonferroni-corrected hypergeometric test. All clusters, including associated data sets and compound scores, are provided in Supplementary Data 3.
r e s o u r c e and compared these to meta-z-scores computed across an external validation set of nine independent studies (Supplementary Data 1) . Z-scores of globally prognostic genes were significantly correlated between PRECOG and the validation set (R = 0.55, P < 2.2 × 10 −16 ; Supplementary Fig. 2a,b) . In addition, pan-cancer prognostic genes were significantly concordant between PRECOG and another validation set comprised of studies profiled by RNA-seq from The Cancer Genome Atlas (TCGA) (R = 0.52, P < 2.2 × 10 −16 ; Supplementary  Fig. 2a,b) . We also evaluated the influence of batch effects 21 on z-score values. Notably, we observed only modest differences in z-scores after batch effect removal (for example, for samples run on different dates) ( Supplementary Fig. 2c-e) .
Pan-cancer prognostic genes
The PRECOG system provides an unprecedented opportunity to quantify commonalities in prognostic genes across a large number of human malignancies. We found that prognostic genes (filtered at |meta-z| > 3.09, or nominal one-sided P < 0.001) are significantly more likely to be shared by distinct tumor types than would be expected by random chance ( Fig. 1c and Supplementary Data 2). This result was reproducible across a broad range of statistical thresholds ( Supplementary Fig. 3a,b) , and it is reminiscent of the high cancer-wide concordance reported among somatic aberrations influencing genome-wide copy number alterations 22 . Conversely, cancer-specific prognostic genes are less frequent than would be expected by random chance ( Fig. 1c and Supplementary Fig. 3a,b) , and they predominantly reflect their tissues of origin ( Supplementary  Fig. 3c and Supplementary Data 2).
To obtain a global map of prognostic patterns, we clustered survivalassociated z-scores across all 166 PRECOG data sets using AutoSOME, an unsupervised method that is not sensitive to outliers and does not require pre-specification of the number of clusters 23 ( Fig. 1d and  Supplementary Data 3) . Prognostic clusters include genes involved in cell adhesion and epithelial-mesenchymal transitions, vascularization, and immunological and proliferative processes (Supplementary Data 3). When clusters were ordered by a metric that integrates gene-level meta-z-scores and cluster size, the two largest clusters were most highly ranked (Fig. 1d, left) . One of these two clusters is broadly associated with inferior outcomes, and is functionally linked to cell proliferation and cell cycle phase (Fig. 1d, right) . Although this cluster is prognostic in many solid tumors, such as breast and lung adenocarcinoma, we found that proliferation genes were not adversely prognostic in some cancers, including colon cancer and acute myeloid leukemia (AML) (Supplementary Data 1) , two malignancies for which the clinical relevance of generally quiescent cancer stem cells has been demonstrated 24, 25 . The other large cluster is associated with favorable survival and is highly enriched in immunological processes and immune-response genes ( Fig. 1d and Supplementary Data 3) , suggesting that the immune microenvironment is a key factor that contributes to favorable survival across cancers.
To further explore cancer-wide prognostic signatures, we used PRECOG to define robust pan-cancer survival models. First, we determined the number of histologies needed to identify genes with maximal prognostic power. Using a cross-validation approach to avoid outliers, we observed quantitative improvements in the significance of pan-cancer prognostic genes until ~30 distinct histologies were sampled, after which additional gains were marginal (Fig. 2a, left) . With this framework, we identified the top ten adverse and top ten favorable prognostic genes, largely consisting of genes that regulate or oscillate with the mitotic cell cycle, as well as markers of distinct lymphocyte subsets (Fig. 2a, right) . Expression of the proto-oncogene FOXM1 (ref. 26 ) was most frequently associated with adverse risk, and it outperformed MKI67, which encodes a protein (Ki-67) that is used clinically as a marker of proliferation 27 (Supplementary Fig. 4a ). Expression of KLRB1 (encoding CD161, a surface marker on several T cell subsets 28 and NK cells; Supplementary Fig. 4b ) was most frequently associated with favorable outcomes. Notably, FOXM1 and KLRB1 were among the top pan-cancer genes in validation sets, including the TCGA RNA-seq data ( Fig. 2b and Supplementary  Fig. 2b ). Bivariate models based on these two genes outperformed either gene alone (Supplementary Data 4) . Moreover, when weighted by their Cox regression coefficients in a training set (Supplementary  Data 4) , a FOXM1-KLRB1 composite score stratified patient survival in diverse internal validation data sets, including carcinomas, brain tumors, and hematopoietic neoplasms (Fig. 2c) , and was prognostic in multivariate models integrating common clinical indices (Supplementary Data 4) . Furthermore, the FOXM1-KLRB1 composite score remained prognostic in external validation data sets, including TCGA RNA-seq data sets ( Supplementary Fig. 4c,d) .
We next asked whether integrating cancers in a meta-analysis might illuminate additional functional elements of biological programs that affect survival. To address this, we evaluated connectivity among top prognostic genes within protein-protein association (PPA) networks. For adversely prognostic genes, a considerably higher connectivity was achieved when considering all cancer histologies together as opposed to separately ( Fig. 2d and Supplementary Data 5), suggesting that individual malignancies in PRECOG contribute complementary information to a pervasive proliferation program (Fig. 2d, middle) . We further characterized this network by integrating PRECOG data with data from ENCODE 20 , ChEA 29 , and mSigDB 30 for 1,006 gene sets defined by shared transcription factor binding sites. Adversely prognostic genes in this network and across PRECOG were most significantly enriched in FOXM1 ChIPseq binding targets 31 (P < 2.2 × 10 −22 ; Supplementary Fig. 4e and Supplementary Data 5), which together with FOXM1 itself, may be drivers of inferior survival. In contrast, we observed no difference in protein-protein connectivity among favorably prognostic genes, whether they were identified from pooled cancers or individual cancers ( Fig. 2d and Supplementary Data 5) . We hypothesized that transcriptome heterogeneity among distinct TALs, which accounts for the majority of favorable pan-cancer prognostic associations, may not be well captured by aggregated PPA studies. In addition, several highly prognostic genes, including KLRB1, are expressed by multiple immune subsets (Supplementary Fig. 4b ). Therefore we performed an 'in silico dissection' of PRECOG to infer the specific leukocyte subsets associated with survival across cancers.
Leukocyte composition in bulk tumors
Infiltration of tumors by specific leukocyte cell subsets such as CD8 + and CD45RO + memory T-lymphocytes has been linked with favorable outcomes in different cancers 2, 32 , whereas other subsets, such as regulatory T cells and macrophages, can confer either good or poor prognosis depending on context [33] [34] [35] [36] . To systematically and comprehensively map compositional differences in TALs and their relationships to survival, we applied a new machine-learning tool known as CIBERSORT 16 . CIBERSORT outperforms previous deconvolution methods with respect to noise, unknown mixture content, and closely related cell types, in statistically estimating relative proportions of cell subsets from expression profiles of complex tissues (for example, bulk tumors) 16 . As input, we used purified Points lying between the parallel gray lines represent insignificant genes in PRECOG, TCGA, or both (nominal two-sided P > 0.05). (c) Kaplan-Meier curves showing differences in overall survival for patients in validation sets stratified by a FOXM1 and KLRB1 expression score (see Online Methods). For each cancer, a median split was used and curve separation was assessed by a log-rank test. Survival units from different studies were standardized to months. Lung cancers were primarily stage I (approximately two-thirds), and the melanoma data consisted primarily of metastatic samples (see Online Methods). 95% confidence intervals are presented in brackets. HR, hazard ratio. (d) Top, genes ranked by mean meta-z-scores across all data sets in PRECOG (n = 23,288 genes). Center, PPA networks for the top 100 genes determined by mean pan-cancer meta-z-scores. Edges are colored to denote experimentally confirmed interactions and/or associations in curated databases (blue edges), and other sources of evidence (gray edges) (see Online Methods and Supplementary Data 5). Functional annotation P values were determined using a Benjamini-Hochberg-corrected hypergeometric test. Genes in the pan-cancer prognostic networks are colored according to the number of cancer-specific PPA networks in which they are also found. 0* indicates genes only found in PPA networks derived from all cancers. Bottom, two metrics of network connectivity are compared among PPA networks for the top 100 prognostic genes derived from all cancers (red diamonds) versus individual cancers and studies in the PRECOG data (gray circles): x axis = node degree, the average number of edges e (i.e., PPAs) per node n (i.e., protein); y axis = algebraic connectivity, a graph theoretic measure of overall network connectedness.
npg r e s o u r c e expression profiles for 22 distinct leukocyte subsets, and defined 'barcodes' of gene expression signatures that robustly distinguish these cell types without requiring cell type-specific marker genes 16 . At a |meta-z-score| > 3.3 (corresponding to two-sided P < 0.001), 28% of these barcode genes (152 of 547) are individually significant in PRECOG, out of 2,851 total pan-cancer prognostic genes at the same significance threshold. This is higher than would be expected by random chance (P < 0.001, chi-squared test). Whether directly or indirectly compared against flow cytometry and immunohistochemistry data, CIBERSORT exhibited robust performance when applied to solid tumors, accurately estimating relative fractions of leukocyte subsets in colorectal cancer and lung adenocarcinoma ( Fig. 3a) , as well as follicular lymphoma 16 .
Applied to PRECOG data, CIBERSORT revealed striking differences in relative leukocyte composition between hematopoietic neoplasms, brain cancers, and non-brain solid tumors ( Fig. 3b and Supplementary Data 6). Variation in TAL content was also consistent and reproducible across independent studies of the same cancer type, including solid tumors (Supplementary Fig. 5a ). Of note, whereas the majority of tumors profiled within PRECOG were unpurified and uncontrolled with respect to tumor content (Supplementary Data 1), CIBERSORT correctly inferred high fractions of plasma cells in multiple myeloma-enriched specimens (Fig. 3b) . Furthermore, as expected, B cell signatures were found to predominate in B cell malignancies ( Fig. 3b) , suggesting that CIBERSORT has general utility for discerning the cell of origin in diverse cancers. Prognostic associations of TALs To complement our gene-centric survival analysis, we assembled a global map of prognostic associations for 22 immune populations across human malignancies (Supplementary Fig. 6a ). We observed considerable variation between cell subsets and cancer-specific outcomes, and many of these associations are statistically significant ( Supplementary Fig. 6b-d) . Pooling cancer types yielded global leukocyte prognostic patterns, in which higher levels of estimated T cell fractions were found to generally correlate with superior survival while increasing levels of myeloid populations primarily correlated with poorer survival. Intra-tumoral γδ T cell 37, 38 and polymorphonuclear (PMN) cell 39, 40 signatures emerged as the most significant favorable and adverse cancer-wide prognostic populations, respectively (Fig. 3c, left) . Moreover, when inferred leukocyte fractions were compared with KLRB1 expression across cancers, γδ T cell and CD8 T cell signatures were most highly correlated ( Supplementary  Fig. 5b ), suggesting a link to the prognostic significance of this gene. We found no relationship between estimated PMN cell fractions estimated by CIBERSORT and known necrotic tissue content, suggesting that intra-tumoral PMN cells are not simply a correlate of tissue necrosis 41 . Furthermore, consistent with previous reports 33, 42 , signatures of tumor-associated M2 macrophages were found to predict worse outcomes than pro-inflammatory M1 macrophages, and anti-CD3/anti-CD28-costimulated, but not resting, CD45RO + memory helper T cells were correlated with superior outcomes.
Prognostic TALs in solid tumors
By comparing leukocyte survival signatures in breast and lung cancertwo of the most highly profiled cancers in PRECOG-we identified two populations, PMN cells and plasma cells (PCs), with unexpectedly strong yet reciprocal relationships to survival (Fig. 3d) . PC signatures are significant predictors of favorable survival across solid tumors in general (Fig. 3c, right) , and we found that they were the most inversely correlated prognostic population to PMN cells (Fig. 4a) when assessed globally in a cross-correlation analysis of human cancers (Supplementary Fig. 5c ). Estimated PC levels were not correlated with tumor stage (Supplementary Fig. 7a ). Because PC signatures were found to be higher in tumors than in adjacent normal tissues ( Supplementary Fig. 7b ), the prognostic value of tumor-infiltrating PCs is unlikely to be a proxy for general immunological health, thus supporting a role for the antigen-driven processes required for their clonal expansion and emergent humoral immune responses 43 . Furthermore, a simple ratio of estimated PMN cells to PCs was found to be significantly prognostic in diverse solid tumors (Fig. 4b) .
To experimentally evaluate the reciprocal survival associations of PMN cell and PC signatures, we assessed their infiltration in 187 lung adenocarcinomas using tissue microarray (TMA) analysis (Supplementary Data 7) . Characteristics of both cell types were observed by H&E staining of tissue sections (Supplementary Fig. 7c,d) , and the presence of tumor-infiltrating plasmacytic cells (i.e., plasmablasts or plasma cells) was confirmed in fresh tumor specimens using both flow cytometry (Supplementary Fig. 7e ) and morphological assessment (Supplementary Fig. 7f ). Moreover, we confirmed an elevated presence of plasmacytic cells in non-small-cell lung cancer (NSCLC) tumors, as compared to normal adjacent tissues (Supplementary Fig. 7g,h) . In serial lung adenocarcinoma tissue sections, we stained for the presence of MPO (myeloperoxidase protein) and IGKC (immunoglobulin kappa constant RNA), markers of PMN cells and PCs, respectively (Supplementary Fig. 8a) . Because B cells express varying levels of IGKC, we also tested for CD20, a surface protein of mature B cells but not PCs (Supplementary Fig. 7e) . We found <10% overlap with CD20, indicating the high specificity of Fig. 8b) . Next, we quantified the staining area for each marker in the tissue array ( Supplementary  Fig. 8c,d ). Despite operating on differing scales and being measured on independent tumor specimens, fractional levels of these three markers measured in situ on TMAs were comparable to the relative infiltrate levels inferred by CIBERSORT (Fig. 4c) . Moreover, in both continuous and binary models, we found a strong relationship between inferior survival and a higher ratio of PMN cells to PCs in lung adenocarcinoma, whether measured in PRECOG (Fig. 4d) , in microarray data sets not included in PRECOG (Supplementary Fig. 8e ), or by surrogate markers in TMA specimens (Fig. 4e) . Furthermore, TMA results remained significant in multivariate models incorporating relevant clinical parameters (P = 0.002; Supplementary Data 7) . Together, these data validate our computational approach, and they demonstrate that tumor-associated PMN cells and PCs exhibit opposite associations with overall survival. Circulating leukocytes, including PMN cells and B lymphocytes, contribute to the tumor microenvironment [44] [45] [46] , and leukocyte frequencies of innate and adaptive effectors in peripheral blood can have prognostic value 43, 47 . Therefore, we examined a subset of NSCLC patients from the TMA with available peri-operative complete blood counts to assess the concordance between levels of circulating leukocytes and TALs. Although intra-tumoral PMN cell-to-PC ratios remained significantly prognostic within this subset (P = 0.035), we found no significant correlation between circulating and infiltrating compartments, and no prognostic value from circulating leukocyte levels (Supplementary Data 7) .
DISCUSSION
Because expression signatures of small numbers of genes 48 and cells 47 can have utility for predicting response to therapy, including anti-tumor agents, we envision that these resources, available at http://precog.stanford.edu, will be useful for the future discovery of predictive biomarkers, including immunotherapies. PRECOG has unique advantages over related resources 49 . First, multiple data sets are included for most human cancers, and the use of a robust survival meta-z approach to integrate studies reduces the potential for erroneous conclusions drawn from single data sets. For example, in contrast to one recent study 15 , we found that molecular markers can indeed add significant prognostic information to clinical variables (see integrated discrimination improvement and net reclassification improvement analyses for FOXM1-KLRB1 in Supplementary Data 4) , which is consistent with our previous work 50 . Nevertheless, we acknowledge that prognostic associations remain modest in some cancers (for example, lung squamous cell carcinoma), and the development of clinically applicable molecular models in such cases may remain challenging. Second, although recent studies have inferred TAL activities in relation to patient outcomes 32, 51, 52 , most have focused on one or two cell types in multiple cancer histologies 32, 52 , have analyzed a relatively small number of markers that are not uniquely expressed by single immune cell types (for example, granzyme A (GZMA) and perforin 1 (PRF1); Supplementary Fig. 4b) 52 , or have studied multiple infiltrating immune cell types in a single cancer histology 51 .
By applying CIBERSORT, a computational method for inferring leukocyte representation in bulk tumors 16 , we identified complex relationships between 22 immune subset signatures and overall survival across 25 cancer histologies. One potential limitation of our approach is the fidelity of input reference profiles, which could deviate from the expression programs and functional states of tumor-associated leukocytes. However, CIBERSORT was developed to be robust with respect to noise, and thus far we have observed strong agreement with ground truth assessments in bulk tumors (see Fig. 3a and ref. 16 ). We identified and validated an intriguing reciprocal prognostic association of PC and PMN cell signatures in diverse and common solid tumors, although the immunological basis for this observation remains unclear. For example, it is unknown whether infiltrating PCs passively reflect nonspecific host immunity or actively contribute to anti-tumor humoral immune responses. Future studies could help define novel tumor-associated antigens targeted by these PCs, with potential implications for new monoclonal antibody therapies. We also speculate that tumor-associated PMN cells may be functionally related to myeloid-derived suppressor cells, which are known to inhibit active T cell anti-tumor immune responses 53 . Indeed, our analysis revealed several broadly favorable prognostic T cell signatures, including γδ and CD8 T cells, whose corresponding cell subsets express KLRB1 (CD161), the top favorable pan-cancer prognostic gene across PRECOG and a marker of enhanced innate immune characteristics in diverse T cell subsets 28 .
The favorable prognostic association of specific TALs across cancers, including effector T cell subsets, is relevant to emerging cancer immunotherapies. Recently, therapeutic antibodies targeting T cell checkpoints, including PD-1 and PD-L1, have yielded unprecedented successes for immunotherapy in some cancers but not others 54 . The immunological diversity underlying the presence or absence of such responses in different cancers and in individual patients remains poorly understood 55 . Our approach provides a framework for characterizing diverse immune effectors as candidate biomarkers for predicting clinical response to these and other novel immunotherapies. It is also amenable to pharmacodynamic measurements that assess the recruitment and/or activation of targeted immune effectors by specific immunotherapies as a means of better understanding treatment responses or failures.
Our results illuminate the prognostic landscape of genes and TALs across human cancers, and they suggest numerous hypotheses for further investigation and clinical translation. Moreover, the data and tools presented here should facilitate a variety of future studies, including the investigation of prognostic biomarkers within molecular subtypes and the assessment of multivariate interactions between genes, TALs, and other clinical indices.
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS
PRECOG assembly and quality control. To identify cancer gene expression data sets with corresponding patient outcome data we queried the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO), European Bioinformatics Institute (EBI) ArrayExpress, the National Cancer Institute (NCI) caArray, and the Stanford Microarray Database for the terms 'survival' , 'prognosis' , 'prognostic' , or 'outcome' . Perl scripts were implemented to download processed and raw data, and associated annotation. For NCBI data, the array platform was determined from the SOFT format file, and the corresponding annotation file was retrieved from GEO. From these, the Probe ID, GenBank accession number, HUGO gene symbol and gene description were extracted based on the internal headers of the SOFT annotation file. The desired fields were specified manually if this automated procedure failed. For older platforms, such as cDNA microarrays, for which annotations had not been recently updated, we re-mapped the probe sequences to HUGO gene symbols via the GenBank or RefSeq accession number through the NCBI Entrez gene identifier. In cases without available accessions, but with the DNA sequence of the probe, we performed the mapping using BLAST-like alignment tool (BLAT) to compare probes to a RefSeq reference and look for unique highest-scoring hits. Scripts were written to extract sample annotation information from GEO SOFT format files and parse them into tables. Since the contents of annotation fields are not semantically enforced, sample data can be contained in various fields, including 'Sample_title' , 'Sample_charac-teristics' , 'Sample_description' and 'Sample_source' . Moreover, not all fields are specified for every sample. To parse this information into a tabular format, we attempted to estimate the correct variable name (column header) by searching for common substrings across samples. In some cases, a data set clearly had survival information, but was not deposited with the genomic data. In such cases, we first searched the supplementary information of the corresponding literature for the missing information. Failing this, we contacted corresponding and first authors, of which roughly half supplied the requested data. All tabulations of clinical annotations were further checked and manually curated. This process included verification of results in selected studies by direct comparison of Kaplan-Meier plots and timescales with those in the corresponding primary publications, as well as consistency of prognostic genes across studies. Separately, errors due to technical issues or the curation process were estimated by comparing annotated gender to the ratio of RPS4Y1 to XIST (male:female) expression levels 56 after microarray normalization, as detailed below (Supplementary Fig. 1a-c) . Furthermore, identical samples present in more than one data set were identified using MD5 checksums for Affymetrix data, and by cross-correlation analysis of expression vectors, and redundant samples were accordingly eliminated.
We applied the following gene expression normalization strategy to allow unification of data from diverse microarray platforms within PRECOG. For Affymetrix GeneChip data, raw CEL files were obtained when possible, and were normalized with the MAS5 algorithm ('affy' package v. 1.26 of Bioconductor v. 1.8 in R 2.15.1), using a custom CDF (Chip Definition File) for probeset summarization, which updates and maps array oligonucleotides to Entrez gene identifiers 57-59 (http://brainarray.mbni.med.umich.edu/ Brainarray/). Each data set, regardless of platform, was quantile normalized separately. Moreover, each gene was log 2 transformed if not already in log space, and was then unit mean/variance standardized across samples within a given data set. Although alternative microarray normalization methods have been proposed (for example, RMA 60 , gcRMA 61 , fRMA 62 , SCAN-UPC 63 ), for survival analysis we did not observe any significant benefit in comparing Affymetrix data normalized as described above to alternate normalization strategies (data not shown). TCGA RNA-seq and clinical data were downloaded from the TCGA Data Coordinating Center using TCGA-assembler 64 . The gene-level RNA-seq data were preprocessed using TCGA-assembler's 'ProcessRNASeqData' function. RNA-seq and clinical data were matched via the patient barcode provided by TCGA.
For each study, the association of each probe on an array platform with survival outcomes was assessed via Cox proportional hazards regression using the 'coxph' function of the R 'survival' package (v. 2.37). Cox coefficients, hazard ratios with 95% confidence intervals, P values, and z-scores were obtained for each array probe. For data sets that had not been processed with Custom CDF, which yields a unique per-gene expression value, survival z-scores for probes were collapsed to the gene level by averaging the z-scores of probes that matched to the same HUGO gene symbol. Z-scores for each gene were summarized across all data sets in each malignancy using Lipták's weighted meta-z test 65, 66 , with weights set to the square roots of sample sizes 67 . To identify genes with cancer-wide prognostic significance, and avoid bias due to cancers with different sample sizes, we further combined weighted meta-z-scores into a single global meta-z-score for each gene using Stouffer's method (unweighted) 66 .
Validation of z-statistics in PRECOG. Using lung adenocarcinoma as a test case, we assessed the relationship between the weighted meta-z-score metric and standard z-scores, the latter of which were derived from a merged expression matrix consisting of GEPs from lung adenocarcinoma studies in PRECOG (Supplementary Data 1) . For this purpose, we selected data sets that had at least 40 stage I samples (indicated in Supplementary Data 1) . To mitigate batch effects, we standardized each gene in each data set such that it had unit mean and variance across stage I samples. Sample annotations were manually reviewed to ensure that staging corresponded to American Joint Committee on Cancer (AJCC) version 6 (2002), based on TNM (tumor-nodes-metastasis) information. Many data sets pre-dated version 7 of AJCC, and did not contain the required detail for annotating to that standard. These refinements and standardizations permitted merging of samples from different data sets comprising different array platforms and different distributions of tumor stage across the cohort. In all, we compared lung adenocarcinoma GEPs from n = 1,106 patients, and found that weighted meta-z scores are significantly correlated with merged z-scores (Spearman's R = 0.9, P < 2.2 × 10 −16 ). We observed similar results when comparing the meta-and merged z-statistics for a compendium of five AML studies, thus validating our use of the meta-z-statistic. Of note, while we applied batch-correction procedures to merge expression data sets before calculating cross-study z-scores, these steps were not necessary with the meta-z metric, as z-scores from individual studies were directly integrated. This suggests that the meta-z approach effectively overcomes batch differences across data sets.
We further evaluated the influence of batch effects 21 within individual data sets using Combat 68 ( Supplementary Fig. 2c-e) . Applied to microarray processing dates in four AML studies, we observed only a modest effect on prognostic z-scores, as pre-and post-batch-corrected data were all highly correlated (R ≥ 0.92, P < 2.2 × 10 −16 ; Supplementary Fig. 2c ). To test whether batch correction of samples profiled by different study sites would improve data quality, we compared pre-and post-batch-corrected expression data from the NCI director's challenge lung adenocarcinoma data set (ca00182) with a control data set consisting of prognostic meta-z scores from a pooled set of all remaining 19 lung adenocarcinoma studies in PRECOG. Little difference in performance was observed for the most prognostic genes, with changes primarily affecting genes whose association with survival outcomes was subtle. (Supplementary Fig. 2d,e) . PRECOG false discovery rate. Whereas z-scores and meta-z-scores were analyzed in this work, Q values for global unweighted meta-z and weighted cancer-specific meta-z-scores were estimated using the FDR method of Storey and Tibshirani 69 , and are available for all analyzed z-score matrices online (http://precog.stanford.edu). Notably, of 23,288 HUGO gene symbols in PRECOG, 4,385 (19%) have a global meta-z significant at Q < 0.05 (|meta-z| > 2.6), and 2,986 (13%) are significant at a Q < 0.01 (|meta-z| > 3.22) (Supplementary Data 1) .
Blinding and sample selection criteria. No blinding was used in this work. Duplicate and non-diagnostic (relapse) samples were excluded from analysis.
Statistical analysis of shared prognostic genes.
To determine an empirical P value for the fraction of overlapping genes in Figure 1c , we randomized gene labels for every cancer, and for each cancer, calculated the fraction of prognostic genes shared with at least one other cancer (again, using |meta-z| > 3.09). We then calculated the median fraction of shared genes across all cancers and repeated the analysis 100,000 times. We performed a similar analysis in Supplementary  Figure 3a ,b, but used 1,000 Monte Carlo iterations to test a broad range of P value and Q value thresholds, considering prognostic genes shared by at least two, three or four tumor types in PRECOG.
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Clustering of the PRECOG z-score matrix. To identify groups of genes with similar prognostic patterns across the entire PRECOG database (166 cancer data sets and 22,461 gene symbols; 827 genes represented in only a small subset of cancers were excluded), we performed unsupervised cluster analysis using AutoSOME 23 . Prior to clustering, columns (i.e., cancer data sets) were preprocessed to unit variance, rows (i.e., genes) were median-centered, and sum of squares = 1 normalization was applied to rows and then columns 23 . AutoSOME was run with a P value threshold of 0.01, 100 ensemble iterations, and otherwise default settings. In all, 665 clusters were identified, and ~50% genes were assigned to the 55 largest clusters (Supplementary Data 3) . Functional annotation for each cluster was assessed using a variety of published gene sets and significance of overlap was determined by a hypergeometric test (for PubMed IDs, see Supplementary Data 3). Gene sets with a Bonferroni-corrected P < 0.01 were considered significant. To further evaluate each cluster, we calculated a global meta-z-score for each gene (as in Supplementary Data 1) , but considered only absolute meta-z-scores to avoid biasing clusters with pancancer prognostic genes with the same survival orientation. We then calculated a compound score for each cluster by applying the same formula used for the unweighted meta-z-score, which weights cluster-wide meta-z-scores by cluster size. Importantly, this formula is not intended to yield a prognostic score in this context, since intra-cluster meta-z-scores are not independent variables. Moreover, our approach is not simply a proxy for cluster size, as the five top-ranking clusters were originally ranked 2, 1, 4,13, and 7 with respect to size. The top five clusters ranked by decreasing compound scores are shown in Figure 1d .
Cross-validation of top prognostic genes. The utility of PRECOG as a cancerwide meta-analysis tool was assessed by cross-validation. Cancer histologies (from Supplementary Data 1) were randomly selected and pooled in a training set, with the number of cancers t ranging from 1 to 31 (of 39) total cancers. For each t, the top ten adverse and favorable prognostic genes were identified using the mean meta-z-score across the training set, and the mean meta-z for the same genes was determined in the remaining (39 − t) cancers (validation set). This process was repeated 100 times for each t, and the results are plotted in Figure 2a . To determine the top prognostic genes across PRECOG, the top ten adverse and favorable prognostic genes in each validation set were recorded at t = 31, and the most frequently occurring genes are shown in Figure 2a .
Construction and assessment of a FOXM1-KLRB1 prognostic model. In brief, we used the coxph function in the R 'survival' package to test the prognostic significance of FOXM1 and KLRB1 in bivariate models across PRECOG (each data set was normalized as described for PRECOG construction). Bivariate models with a P < 0.05 (Wald test) were considered significant. Derivation of the FOXM1-KLRB1 composite score is described in detail below.
To integrate FOXM1 and KLRB1 into a composite score, we analyzed cancer types with at least two independent data sets having a FOXM1, KLRB1 bivariate P < 0.05. Of these, we extracted bivariate coefficients from a randomly selected group of 20% of the corresponding data sets, which served as the training set (n = 8; also see Supplementary Data 4). The median value of each coefficient in the training set was used as an independent weight in the following formula to define a composite score, (FOXM1 × 0.243) + (KLRB1 × −0.169). The median value of the FOXM1-KLRB1 composite score was determined for each left-out data set (validation set), and used to stratify corresponding patients into high and low risk groups, which were then aggregated by cancer type, and subjected to Kaplan-Meier analysis (Fig. 2c) . Importantly, each cancer type in Figure 2c only includes left-out data sets (i.e., validation data) for which FOXM1 and KLRB1 expression values were both available (see Supplementary Data 1 for data sets used). Moreover, the composite score was not re-optimized for RNA-seq when applied to TCGA data.
PRECOG network connectivity analysis. We evaluated the functional coherence of top prognostic genes in PRECOG by interrogation of human PPAs in STRING version 9.0 (ref. 70) . STRING integrates evidence from multiple sources, including curated databases, experimentally confirmed physical interactions, co-expression data, and associations inferred via text mining 70 . We compared the connectivity of STRING networks (for edges with a combined confidence level of at least 0.4) for the top 100 adverse and favorable prognostic genes identified from all cancers (by mean meta-z-score), individual cancers (meta-z-score), and individual data sets (z-score). For each set of proteins, the largest connected component was assessed by two metrics: (i) the average number of associations (i.e., edges) per protein (i.e., node), and (ii) algebraic connectivity, a graphed theoretic measure of overall network connectedness 71 . Only networks with at least ten nodes were considered. Functional enrichment of global networks shown in Figure 2d was performed with ToppFun 72 , and P values were determined using a Benjamini-Hochberg-corrected hypergeometric test.
Gene set analysis of PRECOG clusters and ranked z-scores. Enrichment of biological processes with respect to survival z-scores was assessed in two ways. First, cluster memberships defined by AutoSOME were compared to pre-defined gene sets by hypergeometric test. Comparison gene sets were obtained from the Molecular Signatures Database (mSigDB) 73 , and additional sets of genes that are targets of specific transcription factors were extracted from CHEA 29 and ENCODE 20 . Ranked lists of gene survival z-scores were also analyzed with respect to these gene sets using the 'PreRanked' tool of Gene Set Enrichment Analysis 74 .
Inferring TAL levels in bulk tumor GEPs. The samples profiled within PRECOG primarily represent bulk diagnostic pre-therapy tumor specimens, which often contain a variety of cell types, including diverse TALs. Given the enrichment of lymphocyte markers in favorably prognostic genes across PRECOG (Figs. 1d and 2d) , a method to systematically 'unmix' or deconvolve bulk tumor GEPs in PRECOG may reveal new insights into tumor immunobiology. We recently developed a new approach for CIBERSORT, a machine-learning method that outperformed other approaches in benchmarking experiments 16 . CIBERSORT produces an empirical P value for the deconvolution using Monte Carlo sampling. Like other linear deconvolution methods, CIBERSORT only operates on expression values in non-log linear space 75 .
TAL heterogeneity and prognostic associations. CIBERSORT was applied to all normalized PRECOG GEPs from Affymetrix HGU133 platforms (57 studies and 25 cancers; Supplementary Data 6). In all, 5,782 tumor GEPs were successfully deconvolved (CIBERSORT P < 0.005). For each data set, estimated mRNA fractions of each leukocyte subset were related to survival using univariate Cox regression. Weighted meta-z-scores were determined using the same approach described for PRECOG in order to build an immune-centric version of PRECOG (iPRECOG, Supplementary Fig. 6a) , and unweighted global meta-z-scores were used to summarize pan-cancer leukocyte associations in Figure 3c .
Immune-PRECOG false discovery rate. To differentiate real from stochastic variation in inferred leukocyte prognostic associations, we first compared P values and meta-z-scores in immune-PRECOG (Supplementary Fig. 6b ), as any deviation from a standard normal distribution must be considered when drawing statistical conclusions. We generated 1,000 null meta-z-score matrices by (i) shuffling the cell type fractions inferred for each data set in Supplementary Data 6, and (ii) computing z-scores and corresponding metaz-scores to capture relationships to overall survival. We found a tight correspondence between the distribution of null meta-z-scores and a standard normal distribution (Supplementary Figure 6b) . Having validated the normality of the meta-z-score, we then filtered Supplementary Figure 6a using a range of statistical significance thresholds, and at each cutoff, compared the observed versus expected fractions for all leukocyte prognostic associations (Supplementary Fig. 6c) . At a two-sided P value threshold of 0.05 (|z| > 1.96), we found nearly three times more prognostic associations than would be expected by random chance; at P < 0.01, there is a fivefold enrichment, which continues to increase with lower P value cutoffs (Supplementary Fig. 6c) .
Separately, we performed a similar analysis on the global meta-z-scores shown in Figure 3c . Here, we integrated the null meta-z scores from Supplementary Figure 6c into null global meta-z-scores and recomputed the analysis shown for pan-cancer leukocyte prognostic associations (plotted as the fraction of leukocyte subsets retained at different significance thresholds; Supplementary Fig. 6d ). Taken together, these results explicitly quantify significant versus stochastic variation in leukocyte prognostic associations at different statistical cutoffs, and they allow others to tune the nominal statistical threshold to achieve a desired FDR. Flow cytometry versus CIBERSORT. Flow cytometry analysis of non-small cell lung cancer tumor (n = 13) specimens was performed as described below, and median fractions of CD4 + , CD8 + , CD19 + , CD56 + , and CD14 + populations were normalized by overall CD45 + content (Fig. 3a) . For comparison with CIBERSORT, leukocyte signature matrix populations were grouped into the same cluster of differentiation categories: CD14 + , monocytes, macrophages, and dendritic cells; CD4 + , all T cell subsets except CD8 and γδ T cells; CD8 + , CD8 T cells; CD19 + , naïve and memory B cells, CD56 + , resting and activated NK cells. Median CIBERSORT-inferred fractions for lung adenocarcinoma GEPs, shown in Figure 3a , were determined from two publicly available microarray data sets, GSE7670 (ref. (Fig. 4c,e and Supplementary Fig. 7c-h ), patient samples were retrieved from the surgical pathology archives at the Stanford Department of Pathology and linked to a clinical database using the Cancer Center Database and STRIDE Database tools from Stanford.
Human lung dissociation and flow cytometry. Fresh human lung tumor samples were cut into small pieces and dissociated into single cell suspensions by 45 min of Collagenase I (STEMCELL Technologies) digestion. Dissociated single cells were suspended at 1 × 10 7 per ml in staining buffer (HBSS with 2% heat-inactivated calf serum). After 10 min of blocking with 10 µg µl −1 rat IgG, the cells were stained for at least 10 min with the antibodies listed below. After washing, stained cells were re-suspended in staining buffer with 1µg/ml DAPI, analyzed, and sorted with a FACS Aria II cell sorter (BD Biosciences). Antibodies used for experiments related to Figure 3a: CD45-A700 (cat. no. cat. no. 304024), CD14-PE (cat. no. 325606), CD8-APC (cat. no. 300912), CD4-FITC (cat. no. 357406), CD56-PE-cy7 (cat. no. 318318), and CD19-PerCP-cy5.5 (cat. no. 302230). Antibodies used for enumeration of plasmacytic cells: CD45-PE-cy7 (cat. no. 304016), CD20-PerCP-cy5.5 (cat. no. RUO-340508), CD138-PE (cat. no. 325305), CD38-APC (cat. no. 303509), CD19-A700 (cat. no. 302225), and CD27-FITC (cat. no. 302806). All antibodies were obtained from BioLegend.
Tissue microarray (TMA) cohort. We reviewed patients with lung cancer who had surgically treated disease and paraffin-embedded tumor biopsies from 1995 through June, 2010 for inclusion. Patients with recurrent or metastatic disease samples only were excluded. Medical charts were reviewed to clinically annotate the tumor specimens with demographic, operative procedures, imaging data, and follow-up. Pathology reports were reviewed to confirm specimen type, site, pathology, stage, histology, invasion status and operative procedure. Treated samples (neoadjuvant therapy) were excluded, resulting in a final analysis cohort of 187 pre-treated lung adenocarcinoma tumor specimens with follow-up data.
TMA cohort follow-up. Recurrence was defined by imaging or biopsy and patients with advanced disease or who did not have at least 6 months of follow-up were censored for further analyses. The National Death Index (NDI) was used to define vital status through October 30, 2010. Patients not indicated as dead according to the NDI were assumed to be alive except for those who had left the country or were from other countries (who were censored), as the NDI relies on a social security number for vital status assessment. Synchronous tumors resected over time were eligible for prognostic assessment in patients with two primaries.
TMA construction. The Stanford Lung Cancer TMA was developed from surgical specimens that contained viable tumor from duplicate slides that were reviewed by a board-certified pathologist (R.B.W.). The pathologist was not blinded to sample identity. The area of highest tumor content was marked for coring blocks corresponding to the slides. We used 2-mm cores to build the tissue microarray. These cores were aligned by histology and stage and negative controls were taken from the West Lab and included a variety of benign and malignant tissues (65 cores) that included normal non-lung tissue (12 cores), abnormal non-lung tissue (13 cores), placental markers (23 cores) and normal lung (17 cores). Normal lung consisted of a specimen adjacent to but distinct from tumor over the years 1995-2010 in order to assess the variability of staining by year. OligoDT analysis was performed on the finished array to assess the architecture of selected cores and adequacy of tissue content before target IHC analysis. A co-registered H&E slide was used as well to verify tumor location for cases in which this was unclear on initial inspection.
TMA immunohistochemistry. MPO (DAKO) and CD20 (clone L26, DAKO) immunohistochemistry performed on 4 mm sections using the Ventana BenchMark XT automated immunostaining platform (Ventana Medical Systems/Roche, Tucson, AZ).
TMA RNA in situ hybridization. The RNA in situ hybridization probe for IGKC was designed against chr2: 88,937,790-88,938,290 (hg18) using primer 5′-CTG TTG TGT GCC TGC TGA AT-3′ and the T7 promoter-tagged primer 5′-CTA ATA CGA CTC ACT ATA GGG TTA AAG CCA AGG AGG AGG AG-3′. RNA in situ hybridizations were performed on TA369, as described previously 79 .
TMA microscopy. Eleven slides were scanned at 20× on an Ariol imaging analysis system (originally built by Applied Imaging).
TMA staining quantification and analysis. To facilitate consistency and reproducibility in quantitating TMA staining patterns, we evaluated the performance of GemIdent 80 , a supervised in silico image segmentation system. As an initial exercise, we trained GemIdent on a single lung adenocarcinoma specimen to recognize both IGKC stains and non-tissue background (white space). GemIdent was then applied to 10 TMA specimens to generate separate image masks of both IGKC localization and non-tissue background (i.e., 'empty space'). A custom Perl script was used to process each image mask and quantify the staining area of IGKC for each specimen (by first removing non-tissue white space to calculate the surface area of each tissue). To test the utility of this approach, a board-certified pathologist (R.B.W.) scored IGKC for the same 10 specimens. The pathologist had no knowledge of the results from automated staining, but was not blinded to sample identity. Both assessments were highly correlated (R 2 = 0.98; Supplementary Fig. 8c) . In a separate exercise, two independent operators trained GemIdent on distinct CD20-stained specimens. CD20-stained fractions were then quantified across the entire TMA (n = 187 lung adenocarcinomas) and results were processed as described above. The concordance between independent operators was very high (R 2 ~1; Supplementary  Fig. 8d ). These data support the utility of GemIdent coupled with image post-processing for automated scoring of TMA specimens. We applied this approach to quantitatively score IGKC, CD20, and MPO for all lung adenocarcinoma TMA specimens (for example, see Supplementary Fig. 8a ).
Comparison between TALs and circulating leukocytes. Among patients with available perioperative circulating leukocyte (lymphocyte and PMN cells) counts, we analyzed the sample closest to the date of procedure within −120 to +28 d, where precedence was given to preoperative samples (total n = 46 lung adenocarcinoma patients). As shown in Supplementary Data 7, no relationships were found between circulating leukocyte levels and TALs quantified on the TMA. Moreover, while the ratio of MPO to IGKC levels remained significantly prognostic within this patient subset (P = 0.035), circulating leukocyte levels had no significant relationship to survival. 
